- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03300947
Psilocybin for Treatment of Obsessive Compulsive Disorder (PSILOCD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study seeks to improve our ability to treat and improve the lives of people who have obsessive-compulsive disorder (OCD) by exploring the benefits of psilocybin, a mind-altering drug that changes activity in brain areas believed to be involved in OCD. Anecdotal reports and results from previous research support this idea. This two-phase study will enroll patients with symptomatic OCD who are not taking mind-altering medications or street drugs.
During Phase One, neither participants nor the investigators will know which drugs or doses are administered. This information will be available if it is medically necessary to reveal which drugs and doses were administered. Five subjects in each group will receive study drug a total of four times, separated by one week. During Phase Two, participants will not know which drugs or doses they receive, but the investigators will know. All participants will receive psilocybin at some point during study participation.
Participants will be randomly assigned to one of the following groups:
- Low dose (100 µg/kg) psilocybin,
- High dose (300 µg/kg) psilocybin, or
- Lorazepam (1 mg), a calming medication. Lorazepam is used often for anxiety and will be used to mask which drug participants receive.
Participants will spend approximately 12 hours at the research site under observation during each visit, until they are free of the mind-altering effects of the drug and are determined by the psychiatrist to be safe to go home accompanied by a responsible adult. The effects of low versus high doses, and the additive effects of repeated doses will be analyzed and will be compared to the effects of lorazepam.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID-R).
- Failed at least one adequate attempted routine care treatment.
- Considered safe for independent living
Exclusion Criteria:
- Concurrent psychosis, active substance use disorder, or a personal history of psychosis.
- Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure.
- Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
- Psychiatric comorbidity that may represent an acute risk to their own or others' safety.
- Subjects may not be using antidepressant medication for OCD for at least two weeks before receiving study drug, and they cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
- Women who are pregnant, breastfeeding, or unwilling/unable to practice medically acceptable birth control during the study.
- Allergy to lorazepam.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-dose Psilocybin
Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
|
Psilocybin belongs to the class of hallucinogen or psychedelic drugs.
It is one of the major psychoactive components in mushrooms of the Psilocybe genus ("magic mushrooms").
Other Names:
|
Experimental: High- or Low-dose Psilocybin
Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
|
Psilocybin belongs to the class of hallucinogen or psychedelic drugs.
It is one of the major psychoactive components in mushrooms of the Psilocybe genus ("magic mushrooms").
Other Names:
Psilocybin belongs to the class of hallucinogen or psychedelic drugs.
It is one of the major psychoactive components in mushrooms of the Psilocybe genus ("magic mushrooms").
Other Names:
|
Placebo Comparator: High-dose Psilocybin or Lorazepam
Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
|
Psilocybin belongs to the class of hallucinogen or psychedelic drugs.
It is one of the major psychoactive components in mushrooms of the Psilocybe genus ("magic mushrooms").
Other Names:
A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect.
This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-phase effects on Obsessive-Compulsive symptom severity
Time Frame: weekly Y-BOCS rating prior to ingestion of study drug on Week 1 through 8, and week 9 (follow up week 1)
|
Prospective Assessment of YBOCS (Yale-Brown Obsessive Compulsive Scale) score comparing each psilocybin dose and active placebo (Lorazepam).
|
weekly Y-BOCS rating prior to ingestion of study drug on Week 1 through 8, and week 9 (follow up week 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Incidence of Treatment Emergent Adverse Events
Time Frame: At 0, and 24 hours after blinded medication ingestion
|
Prospective active inquiry of adverse events with the SAFTEE-GI (Systematic Assessment For Treatment Emergent Events-General Inquiry) comparing each psilocybin dose and active placebo (Lorazepam)
|
At 0, and 24 hours after blinded medication ingestion
|
Duration of Effects on Obsessive-Compulsive symptom severity
Time Frame: Follow-up assessments will be conducted weekly over the phone weekly (± 3 days) for one month after last dose, monthly (± 7 days) for three months beginning 28 days after last dose, and then once at 6 months after last dose (± 7 days).
|
Prospective Naturalistic Assessment of YBOCS (Yale-Brown Obsessive Compulsive Scale) after repeated administration of study drug.
|
Follow-up assessments will be conducted weekly over the phone weekly (± 3 days) for one month after last dose, monthly (± 7 days) for three months beginning 28 days after last dose, and then once at 6 months after last dose (± 7 days).
|
Long Term Incidence and Duration of Treatment Emergent Psychiatric Adverse Events
Time Frame: Follow-up assessments will be conducted weekly over the phone (± 3 days) for one month after last dose, monthly (± 7 days) for three months beginning 28 days after last dose, and then once at 6 months after last dose (± 7 days).
|
Prospective Assessment with SCID-I (Structured Clinical Interview for DSM-5 Disorders) psychotic screening tool will assess for onset of psychopathology or hallucinogen induced disorders after repeated use.
|
Follow-up assessments will be conducted weekly over the phone (± 3 days) for one month after last dose, monthly (± 7 days) for three months beginning 28 days after last dose, and then once at 6 months after last dose (± 7 days).
|
Changes in the magnitude of Error Related Negativity (an electroencephalographic biomarker of OCD) assessed by Error-related negativity (voltage) and mid-frontal theta power (time-frequency approach)
Time Frame: Baseline, and 9-10 hours after ingestion of study dose 1, 4, and 8.
|
Prospective Assessment of Error Related brain activity comparing each psilocybin dose and active placebo (Lorazepam).
|
Baseline, and 9-10 hours after ingestion of study dose 1, 4, and 8.
|
Prospective Self-Assessment of Depression Symptoms
Time Frame: Baseline, 24 hours after each dose during 8 week active phase, and during the follow-up phase (weekly for one month after last dose, monthly for three months beginning 28 days after last dose, and then once at 6 months after last dose.
|
Prospective Assessment of Quick Inventory of Depressive Symptomatology (QIDS) Score comparing each psilocybin dose and active placebo (Lorazepam).
|
Baseline, 24 hours after each dose during 8 week active phase, and during the follow-up phase (weekly for one month after last dose, monthly for three months beginning 28 days after last dose, and then once at 6 months after last dose.
|
Prospective Clinician-Rated Assessment of Depression Symptoms
Time Frame: Baseline, 4 weeks, 8 weeks, and during the follow-up phase (weekly for one month after last dose, monthly for three months beginning 28 days after last dose, and then once at 6 months after last dose
|
Prospective Assessment of Montgomery-Asberg Depression Rating Scale (MADRS) Score comparing each psilocybin dose and active placebo (Lorazepam).
|
Baseline, 4 weeks, 8 weeks, and during the follow-up phase (weekly for one month after last dose, monthly for three months beginning 28 days after last dose, and then once at 6 months after last dose
|
Changes in functional connectivity: 1) between the Caudate Nucleus (CN) and Orbital Frontal Cortex (OFC); 2) within the default mode network (DMN).
Time Frame: Imaging at baseline, and 9-10 hours post ingestion on weeks 1, 4, and 8. YBOCS at baseline and 8 hours after ingestion at weeks 1, 4, and 8.
|
Prospective Assessment of Functional Connectivity in CN and OFC and in DMN comparing each psilocybin dose and active placebo (Lorazepam).
Also examining whether magnitude of symptom reduction is related to changes in functional connectivity.
|
Imaging at baseline, and 9-10 hours post ingestion on weeks 1, 4, and 8. YBOCS at baseline and 8 hours after ingestion at weeks 1, 4, and 8.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francisco A. Moreno, MD, Professor of Psychiatry and Associate Vice President, Diversity and Inclusion
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Personality Disorders
- Anxiety Disorders
- Compulsive Personality Disorder
- Obsessive-Compulsive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Hallucinogens
- Lorazepam
- Psilocybin
Other Study ID Numbers
- 1707613822
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-compulsive Disorder (OCD)
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingObsessive Compulsive Disorder (OCD)United States
-
University of LeipzigGerman Research Foundation; Philipps University Marburg Medical CenterCompleted
-
New York State Psychiatric InstituteCompletedObsessive-Compulsive Disorder (OCD)United States
-
Baylor College of MedicineBrown University; Duke University; University of Washington; Mclean Hospital; William... and other collaboratorsNot yet recruitingObsessive-Compulsive Disorder (OCD)United States
-
New York State Psychiatric InstituteCompletedObsessive Compulsive Disorder (OCD)United States
-
The University of Texas Health Science Center,...MedtronicRecruitingObsessive-Compulsive Disorder (OCD)United States
-
Haukeland University HospitalSorlandet Hospital HFActive, not recruitingObsessive Compulsive Disorder (OCD)
-
University of BathSouth London and Maudsley NHS Foundation Trust; Avon and Wiltshire Mental Health...UnknownObsessive Compulsive Disorder (OCD)United Kingdom
-
Assistance Publique - Hôpitaux de ParisRecruitingObsessive Compulsive Disorder OCDFrance
-
Xuanwu Hospital, BeijingNot yet recruiting
Clinical Trials on Psilocybin 300 mcg/kg
-
Janssen Pharmaceutical K.K.Completed
-
Tarix PharmaceuticalsConstant Therapeutics LLCTerminatedMyelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Hodgkins Lymphoma | Non Hodgkins Lymphoma | Double Cord Blood TransplantUnited States
-
Mayo ClinicRecruitingPain ControlUnited States
-
Yale UniversityHeffter Research Institute; Ceruvia Lifesciences; CH TAC LLCCompleted
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
MedImmune LLCCompletedChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaUnited States, Poland
-
MedImmune LLCCambridge Antibody TechnologyTerminatedLeukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab PasudotoxUnited States, Poland
-
Bausch Health Americas, Inc.CompletedRheumatoid ArthritisUnited States
-
Eisai Inc.Dr. Reddy's Laboratory; Citius PharmaceuticalsCompletedPersistent or Recurrent Cutaneous T-Cell LymphomaUnited States, Australia, Puerto Rico
-
Protalex, Inc.CompletedArthritis, RheumatoidUnited States